Linee guida

Management dell’encefalopatia epatica

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatology. 2014 Aug;60(2):715-35. Epub 2014 Jul 8.

Leggi tutto...

Valutazione per il trapianto di fegato

Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown Jr. And Michael Fallon .Hepatology  2014 Article first published online: 25 FEB 2014

Leggi tutto...

Immunosoppressivi e Anti-TNF nell’induzione e mantenimento della remissione nel Morbo di Crohn

American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

Terdiman JP1, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT; AGA Institute Clinical Practice and Quality Management Committee.

Collaborators (8)Dorn SD, Dudley-Brown SL, Lim JK, Palmer LB, Romero Y, Rubenstein JH, Weinberg DS, Yang YX. Gastroenterology. 2013 Dec;145(6):1459-63.

 

KEYWORDS: AGA, American Gastroenterological Association Institute, CD, Crohn's disease, Development and Evaluation, GRADE, Grading of Recommendations Assessment, PICO, TNF, and outcome, comparator, intervention, population, tumor necrosis factor

Leggi tutto...

Management 2014 dell’epatite C una consensus UK

Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy.M. H. Miller,K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski and J. F. Dillon .Alimentary Pharmacology & Therapeutics 2014 Article first published online: 22 APR 2014

Background

Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates. Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting.

Leggi tutto...

Management delle infezioni in corso di cirrosi

Bacterial Infections in Cirrhosis. A Position Statement based on the EASL Special Conference 2013.

Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Thierry Gustot T, Bernardi M, Canton R1, Agustin Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P. J Hepatol. 2014 Feb 11 [Epub ahead of print]

 

Bacterial infections are very common and represent one of the  most important reasons of progression of liver failure, development of liver-related complications, and mortality in patients with cirrhosis. In fact, bacterial infections may be a triggering factor for the occurrence of gastrointestinal bleeding, hypervolemic hyponatremia, hepatic encephalopathy, kidney failure, and development of acute-on-chronic liver failure.

Leggi tutto...

Informazioni aggiuntive